about
Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study.Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective?Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study.Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS.Oral contraceptives combined with interferon β in multiple sclerosis.Relationship between Prolactin Plasma Levels and White Matter Volume in Women with Multiple SclerosisDentate nucleus connectivity in adult patients with multiple sclerosis: functional changes at rest and correlation with clinical features.Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study.A lesion topography-based approach to predict the outcomes of patients with multiple sclerosis treated with Interferon Beta.Investigating the phenomenon of "cognitive-motor interference" in multiple sclerosis by means of dual-task posturography.The impact of interferon beta and natalizumab on comorbid migraine in multiple sclerosis.Mood and coping in clinically isolated syndrome and multiple sclerosis.Role of Cerebellar Dentate Functional Connectivity in Balance Deficits in Patients with Multiple Sclerosis.A low-cost cognitive rehabilitation with a commercial video game improves sustained attention and executive functions in multiple sclerosis: a pilot study.Neuroimaging techniques to assess inflammation in Multiple Sclerosis.Lesion symptom map of cognitive-postural interference in multiple sclerosis.Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs.Task-dependent deterioration of balance underpinning cognitive-postural interference in MS.Determinants of the severity of comorbid migraine in multiple sclerosis.Multiple Sclerosis: Changes in Thalamic Resting-State Functional Connectivity Induced by a Home-based Cognitive Rehabilitation Program.Natalizumab discontinuation and disease restart in pregnancy: a case series.Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experienceMulti-scale resting state functional reorganization in response to multiple sclerosis damageCognitive fatigability is a quantifiable distinct phenomenon in multiple sclerosisMinimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosis
P50
Q31162052-C98F933F-9965-4BEE-B371-BFC47279CA27Q33830080-70B99E35-67F8-475D-A212-CA279EC210D3Q34527935-D2F5D327-B042-4FE0-8268-762EE30E3AB6Q34653997-23AF24B3-F2D8-4EE0-9D1A-51155E84B0B1Q35764738-764BA67B-46B7-48F2-A034-AB7EF6F64AD8Q35876713-5ED241D2-5AEA-46A7-81C3-C2BA2B6E0882Q36076489-54D7349D-3EF7-4C08-86F0-C8C6A2D95D60Q36367612-2D21A5FE-E9FF-4297-B1C2-632C953C48BEQ38837958-02EB9AC1-3FC8-4711-B2BD-A90E389263C2Q41225498-96E60477-99D4-45E6-B8A9-43CB97BFD419Q46232933-56607006-9052-4C17-8B3D-92ED3533DE68Q46959470-AE37EEB9-FD2A-4338-A0ED-294A379019A8Q47186512-AA8F35B0-67D2-4C3B-91D2-D7C4D9E56E92Q48059793-A40FA1AB-FB6C-4D0D-ABBC-70ED237711E3Q48170522-3B25F597-1100-42E6-9F73-40E92BBC4E85Q48247605-B939A24C-361E-4660-BCF0-D017E1739103Q48333424-3CFF2456-420F-4BF0-9B9F-BFE4DFDC7C6DQ48572800-ACA56118-9E1C-4388-9A81-9183BDD49EC7Q48671319-C2804928-D9D8-42D3-BF2C-B47FA5A30207Q48852876-33AF6478-6780-48D2-ABA9-56608580094FQ51063274-0A70609E-EB3F-49A0-A35B-C6AFC1E386A8Q57217552-DAA9D174-C211-48A4-AB8F-BDDD0A4FA250Q90439628-8EEF8B68-0260-4BB2-A421-F3050556B220Q91290975-FF122F7E-7EE9-4B33-A4F3-F6FE17088483Q92888410-009AACBD-0CBA-48B1-B8D5-D57886541596
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Laura De Giglio
@ast
Laura De Giglio
@en
Laura De Giglio
@es
Laura De Giglio
@nl
type
label
Laura De Giglio
@ast
Laura De Giglio
@en
Laura De Giglio
@es
Laura De Giglio
@nl
prefLabel
Laura De Giglio
@ast
Laura De Giglio
@en
Laura De Giglio
@es
Laura De Giglio
@nl
P106
P1153
11339012200
P21
P31
P496
0000-0001-9018-7320